A MedicalXpress report has drawn attention to emerging evidence that discontinued cadaver-derived human growth hormone (c-hGH) treatments administered to children between the 1950s and 1985 may be linked to rare cases of Alzheimer's disease (AD) decades later. While the article correctly notes that AD is a neurodegenerative disorder and that the implicated treatments are no longer used, it stops short of contextualizing the findings within the broader history of prion-like protein transmission, the limitations of the supporting data, and the wider implications for medical safety surveillance.

The primary evidence stems from an observational case series published in Nature Medicine in 2024 (Banerjee et al.), which examined eight individuals who had received c-hGH and later developed early-onset dementia. Five met clinical criteria for Alzheimer's disease, with biomarker and imaging findings consistent with AD pathology but lacking typical genetic mutations (APP, PSEN1, PSEN2). This was not a randomized controlled trial but a retrospective analysis of a small, highly selected cohort exposed to batches of c-hGH later associated with Creutzfeldt-Jakob disease (CJD) transmission. Sample size is a clear limitation; the study quality is best described as hypothesis-generating rather than definitive. No significant conflicts of interest were declared, though several authors have long-standing expertise in prion research.

This work builds directly on a 2015 Nature paper (Jaunmuktane et al.) that first demonstrated postmortem amyloid-β deposition in the brains of people who died from iatrogenic CJD after receiving the same c-hGH preparations. That earlier study (postmortem neuropathological analysis, n=8) provided the mechanistic foundation: amyloid-β can behave in a prion-like manner, with misfolded seeds capable of templating further aggregation when introduced exogenously. The current findings extend this from purely pathological evidence to clinical disease, revealing a pattern of iatrogenic neurodegenerative disease that was largely unanticipated when c-hGH was first deployed.

Original coverage missed several critical connections. First, the same pituitary-derived material caused over 200 documented cases of iatrogenic CJD worldwide before its withdrawal in 1985, showing that one biologic product could transmit multiple proteopathic seeds. Second, similar iatrogenic amyloid transmission has been observed in patients who received cadaveric dura mater grafts. These cases illustrate a recurring theme: medical products derived from human central nervous system tissue carried unrecognized risks of protein-misfolding disease. The coverage also underemphasizes that modern recombinant growth hormone, in use since 1985, carries no such risk.

The editorial lens here is clear: these rare cases expose the long-term iatrogenic risks inherent in past medical practices that relied on pooled human tissues before prion biology was fully understood. They deserve urgent attention because they highlight deficiencies in long-term pharmacovigilance. Thousands of children were treated with c-hGH; only a small fraction have been systematically followed into late adulthood. This gap in follow-up means we may be underestimating the true burden. It also raises uncomfortable questions about other historical uses of human-derived biologics and the adequacy of current safeguards for emerging therapies involving proteins or tissues.

Synthesizing the MedicalXpress report, the 2024 Nature Medicine observational series, and the 2015 Nature neuropathological study reveals a consistent but still limited signal: under very specific iatrogenic conditions, amyloid-β pathology can be seeded and may lead to clinical dementia 30–40 years later. The absolute risk remains low, and there is no evidence of person-to-person transmission through daily contact, blood donation, or modern medical procedures. Yet the findings reinforce the principle that biological medicines can have unanticipated, multi-decade consequences. Greater investment in lifelong registries for historical treatment cohorts is warranted to protect public health and inform the safe development of future therapies.